Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1β induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase

Journal of Clinical Biochemistry and Nutrition

Volumn 45, Issue 1, 2009, Pages 86-92

  Tanigawa, Tetsuya ^a   Watanabe, Toshio ^a   Higuchi, Kazuhide ^b   Machida, Hirohisa ^a   Okazaki, Hirotoshi ^a   Yamagami, Hirokazu ^a   Watanabe, Kenji ^a   Tominaga, Kazunari ^a   Fujiwara, Yasuhiro ^a   Oshitani, Nobuhide ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

ERK; IL 1 ; Lansoprazole; NF B; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LANSOPRAZOLE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; MONOCYTE; PROTEIN PHOSPHORYLATION;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 67849115751     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.08-267     Document Type: Article

References (27)

1. Blaser, M.J., Chyou, P.H., and Nomura, A.: Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res., 55, 562-565, 1995.
2. Correa, P. and Houghton, J.: Carcinogenesis of Helicobacter pylori. Gastroenterology, 133, 659-672, 2007.
3. Peek, R.M., Jr. and Crabtree, J.E.: Helicobacter infection and gastric neoplasia. J. Pathol., 208, 233-248, 2006.
4. Packey, C.D. and Sartor, R.B.: Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J. Intern. Med., 263, 597-606, 2008.
5. Watanabe, T., Higuchi, K., Kobata, A., Nishio, H., Tanigawa, T., Shiba, M., Tominaga, K., Fujiwara, Y., Oshitani, N., Asahara, T., Nomoto, K., Takeuchi, K., and Arakawa, T.: Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut, 57, 181-187, 2008. (Pubitemid 351158044)
6. Konaka, A., Kato, S., Tanaka, A., Kunikata, T., Korolkiewicz, R., and Takeuchi, K.: Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol. Res., 40, 517-524, 1999.
7. Robert, A. and Asano, T.: Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins, 14, 333-341, 1977. (Pubitemid 8171147)
8. Smith, P.D., Ochsenbauer-Jambor, C., and Smythies, L.E.: Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev., 206, 149-159, 2005.
9. Akira, S. and Takeda, K.: Toll-like receptor signalling. Nat. Rev. Immunol., 4, 499-511, 2004.
10. Maeda, S., Akanuma, M., Mitsuno, Y., Hirata, Y., Ogura, K., Yoshida, H., Shiratori, Y., and Omata, M.: Distinct mechanism of Helicobacter pylori-mediated NF-κB activation between gastric cancer cells and monocytic cells. J. Biol. Chem., 276, 44856-44864, 2001.
11. Smith, M.F. Jr., Mitchell, A., Li, G., Ding, S., Fitzmaurice, A.M., Ryan, K., Crowe, S., and Goldberg, J.B.: Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. J. Biol. Chem., 278, 32552-32560, 2003.
12. Becker, J.C., Grosser, N., Waltke, C., Schulz, S., Erdmann, K., Domschke, W., Schroder, H., and Pohle, T.: Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem. Biophys. Res. Commun., 345, 1014-1021, 2006.
13. Handa, O., Yoshida, N., Fujita, N., Tanaka, Y., Ueda, M., Takagi, T., Kokura, S., Naito, Y., Okanoue, T., and Yoshikawa, T.: Molecular mechanisms involved in anti- inflammatory effects of proton pump inhibitors. Inflamm. Res., 55, 476-480, 2006.
14. Ichikawa, H., Yoshida, N., Takagi, T., Tomatsuri, N., Katada, K., Isozaki, Y., Uchiyama, K., Naito, Y., Okanoue, T., and Yoshikawa, T.: Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J. Gastroenterol., 10, 2814-2817, 2004.
15. Kuroda, M., Yoshida, N., Ichikawa, H., Takagi, T., Okuda, T., Naito, Y., Okanoue, T., and Yoshikawa, T.: Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin- induced rat enteritis. Int. J. Mol. Med., 17, 89-93, 2006.
16. Sasaki, T., Yamaya, M., Yasuda, H., Inoue, D., Yamada, M., Kubo, H., Nishimura, H., and Sasaki, H.: The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur. J. Pharmacol., 509, 201-210, 2005.
17. Suzuki, M., Mori, M., Fukumura, D., Suzuki, H., Miura, S., and Ishii, H.: Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. J. Gastroenterol. Hepatol., 14, 27-31, 1999.
18. Suzuki, M., Nakamura, M., Mori, M., Miura, S., Tsuchiya, M., and Ishii, H.: Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J. Clin. Gastroenterol., 20, S93-S96, 1995.
19. Wandall, J.H.: Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut, 33, 617-621, 1992.
20. Yoshida, N., Yoshikawa, T., Tanaka, Y., Fujita, N., Kassai, K., Naito, Y., and Kondo, M.: A new mechanism for anti- inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment. Pharmacol. Ther., 14, S74-S81, 2000.
21. Suzuki, M., Suzuki, H., and Hibi, T.: Proton pump inhibitors and gastritis. J. Clin. Biochem. Nutr., 42, 71-75, 2008.
22. Naito, Y.: Anti-inflammatory and anti-oxidative properties of proton pump inhibitors. J. Clin. Biochem. Nutr., 41, 82-83, 2007.
23. Nakamura, M., Matsui, H., Serizawa, H., and Tsuchimoto, K.: Lansoprazole Novel Effector Sites Revealed by Autoradiography: Relation to Helicobacter pylori, Colon, Esophagus and Others. J. Clin. Biochem. Nutr., 41, 154-159, 2007.
24. Sanceau, J., Kaisho, T., Hirano, T., and Wietzerbin, J.: Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NFκB, and Sp1 transcription factors. J. Biol. Chem., 270, 27920-27931, 1995.
25. Durando, M.M., Meier, K.E., and Cook, J.A.: Endotoxin activation of mitogen-activated protein kinase in THP-1 cells; diminished activation following endotoxin desensitization. J. Leukoc. Biol., 64, 259-264, 1998.
26. Zhang, F.X., Kirschning, C.J., Mancinelli, R., Xu, X.P., Jin, Y., Faure, E., Mantovani, A., Rothe, M., Muzio, M., and Arditi, M.: Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem., 274, 7611-7614, 1999.
27. Bhattacharyya, A., Pathak, S., Datta, S., Chattopadhyay, S., Basu, J., and Kundu, M.: Mitogen-activated protein kinases and nuclear factor-κB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem. J., 368, 121-129, 2002.